Summary.-The profiles of 4 acute-phase reactant proteins (APRPs) (haptoglobin (HPT)-, a, antitrypsin (AAT), al acid glycoprotein (AGP) and prealbumin (PALB)) have been studied during the evolution of bowel cancer. Serial measurements of these APRPs can add to the information obtained from measurements of the level of CEA and hepatic enzymes during the monitoring of postoperative patients. There is considerable stability in the profile in a given individual in health. Rises of AAT and AGP are associated with metastases. High levels of HPT may suggest involvement of the bowel wall by recurrent cancer. PALB levels tend to reflect the nutritional status. A discriminant function based on the log CEA, AAT and AGP preoperative blood levels can considerably improve on the predictive value attained using CEA levels alone.
THERE is now a substantial body of evidence from Europe and North America that sequential measurement of the plasma carcinoembryonic antigen (CEA) concentrations can provide an earlier warning of the recurrence and metastasis of large bowel cancer (see Cooper, 1976 and Go, 1976 for reviews). However, this test alone has certain limitations, since CEA may not be elevated in primary tumours, especially Dukes A and B lesions, or when there is a minimal residual tumour load remaining after resection of the primary tumour. The probable site of the metastases is not indicated by the level of CEA, although this omission can be overcome, at least in part, by the synchronous measurement of serum enzymes that reflect disturbances of hepatic function (Cooper et al., 1975; Munjal et al., 1976; Schwartz, 1976) but these tests do not become positive until there is a considerable tumour load, as judged by inspection of the liver at laparotomy (Cooper et al., 1976a) . In a search for other biochemical tests that might be used to form an array for the monitoring of colorectal cancer, our attention has turned to the a globulins. In common with many forms of cancer, colorectal cancer often induces a disturbance of the a globulins, and an initial study of the behaviour of haptoglobin, a member of the a globulin group of plasma protein (Cooper et al., 1976b) , indicated that the change in the profile of several acute-phase reactant proteins (APRPs) warranted further study. In this paper we report changes in the profile of four APRPs, measured both in horizontal studies to relate the change of profile with evolution of the disease in individual patients, and in vertical studies to relate the general alterations encountered in various clinical stages to the natural history of the cancer and its metastases. This study does not attempt to mirror completely our total experience of CEA, which is now based on several thousand estimations in colorectal cancer. It has been designed, using selected test samples, to evaluate whether a profile of APRPs can provide information complimentary to CEA and hepatic function tests. We also describe how the application of a stepwise logistic discriminant analysis to the components of the array measured in preoperative patients can provide a prognostic index that is more powerful than CEA alone.
PATIENTS AND METHODS
Patients. One hundred and two patients, aged 45-92 (mean 68) years, were studied.
The 237 samples of blood tested included 70 taken preoperatively from patients at the time of their first presentation. The followup samples were selected from our serum bank, held at -25°C, on the basis of the known pattern of evolution of the metastatic cancer, or evidence of potential cure as indicated by absence of evidence of recurrence and a normal CEA for 1-2 years after resection of the primary cancer. For convenience, the material has been stratified with respect to a number of clinical and laboratorybased criteria. Primarv tumours were divided into: (1) those in which surgery was apparently successful (Dukes A, B and C) without any residual disease and patients have remained tumour free for at least one year; (2) apparently successful resections that subsequently developed evidence of metastases during a follow-up of 1-2 years; and (3) patients in whom the primary lesion was complicated by overt metastases which varied considerably in amount from minimal residual disease undetectable after the wound was closed to marked indicator lesions, especially in the liver.
The postoperative samples were grouped as: (a) tumour-free, in which there was no evidence of recurrence clinically and the CEA was < 30 ng/ml; (b) suspicious, in which the CEA was > 30 ng/ml but there was no evidence of tumour detected clinically; (c) pelvic and peritoneal metastases based on clinical findings; and (d) hepatic metastases that had either been observed at laparotomy or diagnosed subsequently as the result of a progressive elevation of CEA, associated with a rising y glutamyl transpeptidase and 5' nucleotidase.
Methods.-The plasma CEA was measured using the assay described by Laurence et al. (1972) , the upper limit of normal being taken as 15 ng/ml. A level of 30 ng/ml has been chosen as the decision point, since a rise above this value in a postoperative patient carries a probability of 0 95 that there is an underlying recurrent cancer. Gamma glutamyl transpeptidase (GGT) and 5' nucleotidase (NTD) were measured as described previously (Cooper et al., 1975) .
Haptoglobin (HPT), oil-acid glycoprotein (AGP) and prealbumin (PALB) were measured by single radial immunodiffusion, using antisera and standard preparations obtained from Behringwerke AG, Marburg/Lahn, W. Germany. The HPT phenotypes were identified by electrophoresis on gradient pore polyacrylamide gels (Baxter and Rees, 1974) . The correction factors applied were x 0-6 for Hp 1: 1, x 1-3 for Hp 2: 1 and x 1-5 for Hp 2: 2. Antitrypsin (AAT) and ceruloplasmin (CPL) were measured by automated immunoprecipitation (Ritchie, 1973) , antisera being obtained from Atlantic Antibodies Inc, Westbrook, Maine (AAT) and Behringwerke AG (CPL).
The normal range for these plasma proteins in our laboratories is HPT 0-5-2-5 g/l, AAT 1 8-3-0 g/l, AGP 0-6-10 g/l, PALB 0-2-0-4 g/l and CPL 01-0-3 g/l. These ranges are applicable to a healthy population over the age of 40 years, but do not necessarily apply directly to a population weighted in excess of 65 years, which would more closely approximate the cancer patients under study whose median age is 68 years.
Statistical analysis.-The grouped data are expressed as group means and the standard deviation (s.d.) and standard error (s.e.) of the mean. The discriminant function for the separation of patients who remained tumourfree for at least 1 year after surgery (Group I) from those who developed metastases after an apparently curative resection (Group 2) was derived by logistic discriminant analysis (Anderson, 1972) .
A step-wise approach was taken to the establishment of the discriminant function. Thus the potential discriminators were considered one at a time, and the one (log10 CEA) which best separated the two groups was selected. Then the variable which best assisted logl0 CEA to separate the groups was selected. This procedure continued, adding discriminant variables one at a time until the extra separation given by the next ' best" discriminator was no longer statistically significant, as judged by an asymptotic loglikelihood ratio test. In the order selected by this procedure, the discriminant variables were log1o CEA, cxl-antitrypsin and oil-acid glycoprotein, and the discriminant function was estimated to be: I = 6-2 2-6x-1 16x2 + 1 3X3, where xi and x3= surgery. = log1o CEA ng/ml, x2 AAT g/l AGP g/l as measured prior to
RESULTS

Horizontal studies
The behaviour of the profile of APRPs in colorectal cancer is best illustrated by considering their patterns during the follow-up after surgical treatment of the primary tumour. The following examples have been selected to indicate the chronological change in a battery of proteins which depicts graphically the events underlying the larger series that have been classified into a number of discrete events in the vertical studies. Fig. 1 shows the evolution of the APRPs in a patient who developed hepatic metastases after an apparent disease-free interval. Six months prior to the start of monitoring, the patient had undergone a curative resection of a Dukes Cl tumour of the colon. During the course of the study the CEA rose from 26 to 125 ng/ml and the GGT was 60 iu/l at the last reading: subsequently the patient deteriorated rapidly, developing obvious clinical signs of hepatic metastases, and died 4 months after the last set of measurements. At the time of the last reading there had been no clinical evidence of metastases. Fig. 2 shows the stability of the proteins after the 4th month following the resection of a Dukes B carcinoma of the colon in a woman aged 56 years. The first observation was made the day before surgery. At that time the CEA was 84 ng/ml and all the APRPs were raised. Subsequently the CEA has remained 10 ng/ml and the APRPs have been within normal limits. Fig. 3 demonstrates the pattern of the APRP profile in a woman aged 72 years who had a Dukes B tumour of the rectosigmoid excised in May 1973, and 9 months later was found to have a local recurrence that required excision. Subsequently she developed progressive spread of the tumour in the pelvis and peritoneal cavity, and died 7 months later. Plasma AAT, a antitrypsin; AGP, acid glycoprotein.
HPT, haptoglobin;
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Vertical studies in postoperative patients
The general evolution of the changes in the APRP, GGT and CEA levels are illustrated in Tables I and II cated in the methods section, the definition of a " normal " range is difficult-we consider that a good useful standard is best provided by the values found in postoperative patients in whom prolonged follow-up has proved that they are cured. This has been used to select the discriminant levels adopted in Table II Fig. 6 shows the extent to which the logistic discriminant function can separate the patients in Groups 1 and 2, and Fig. 7 demonstrates the application of the same function to the CEA, AAT and AGP values in patients found to have metastases at operation. The predictive value of these tests is summarized in the following statement.
When a " curative" operation was performed, 18 years, whilst only 3/27 (11 %) with a positive index recurred in the same period; there were a further 3 patients with an index of 0, all of whom have remained without recurrence. Similarly, of Group III patients, who had metastatic cancer at operation, varying from advanced disease to minimal residual cancer, 19/22 (86%) had a negative index. The probability of curative surgery diminished as the negative value of index increased. An index of > 0 was associated with a curative operation in 27/33 instances (82%); 5/6 of the failures with a positive discriminant had indices of < 0-5. The advantage of the discriminant over the CEA alone as a prognostic factor can be seen by comparing the distribution of CEA (Fig. 5) with the corresponding discriminant values (Figs. 6 and  7) . The advantage of the system lies in helping to allocate the CEA up to 100 ng/ ml to the correct group. The value of GGT did not aid the discriminant, as high values were always associated with a high CEA. However, a negative discriminant with a raised GGT often increases the probability of finding hepatic metastases at laparotomy.
DISCUSSION
The levels of various APRPs are frequently abnormal in cancer (see Koj, 1974 and Bacchus, 1975 for review). However, their reaction is non-specific: disturbances of various individual APRPs can be caused by injury, acute and chronic infection and various inflammatory and degenerative diseases. In the past, many vertical studies of individual components of the spectrum of APRPs have been studied as potential cancer tests and discarded. Even with the present increased precision of measurement, the APRPs alone are not a test for the presence of cancer. In bowel cancer this is especially true, as primary cancers may produce alterations of the APRPs that are closely mirrored by the responses to inflammatory diseases of the large bowel (Marner, Friborg and Simonsen 1975) so that the APRP profile does not help in the differential diagnosis of bowel cancer in which the CEA is normal or slightly raised, for this combination can be found in any of the inflammatory states. Nevertheless, gastrointestinal symptoms with a disturbed APRP profile, with or without an elevated CEA, are a strong indication for investigation of the gastrointestinal tract, and a persistent abnormality of the protein profile might be taken as an indication of a need to re-examine the bowel, if no lesion can be detected on the first x-ray studies. About 7 % of colon tumours may not be detectable at the time of the first radiological examination (Lauer, Carlson and Wollaeger, 1965) .
The relative stability of the protein profile in a given individual, as long as his health remains in steady state, is an essential property that makes protein profiling useful in cancer monitoring. The present studies have confirmed this stability, which was suggested by previous studies of HPT (Cooper et al., 1976b) . Random measurements of protein profiles after bowel surgery are of little value, other than that they may confirm suspicion -of metastases that have been suggested by an elevated CEA. The profiling system only becomes a valuable indicator of tumour recurrence when it is measured sequentially. A similar experience has been reported by others using single or several APRPs (Mueller, Handschumacher and Wade, 1971; Vickers, 1974) . We have found that APRPs can add to the information provided by CEA and liver enzyme markers for monitoring the chemotherapy of colorectal cancer (Bullen et al., 1976) . However, the APRPs have the disadvantage of being sensitive to signals produced by wounded tissues, so that stability may not be reached for 3 months after major surgery such as abdominoperineal excision of the rectum. AAT and AGP are both increased in metastatic cancer and tend to be load-dependent. This effect is also found in other forms of adenocarcinoma such as breast, stomach and transitionalcell tumours of the bladder (Milford Ward et al., unpublished data) . However, about 14% of the Caucasian population in the United Kingdom will be of a non-MAAT phenotype, which results in the levels of AAT being lower than normal (Cook, 1974) . HPT is a particularly sensitive indicator. High levels may accompany uncomplicated primary bowel cancer, the levels tend to remain above the normal range in patients who have had a resection, and are not influenced by the presence or absence of a colostomy. We have the impression, based on 4 patients, that an unexpected and sustained rise of HPT after resection of a colorectal cancer may indicate local recurrence or metastases involving the bowel wall.
PALB was added to the array as it is a negative reactant, and in longitudinal studies its slow fall may be the first sign of deterioration. PALB tends to take several months to reach its highest level in patients treated successfully, and also may be restored to the normal range when patients respond favourably to chemotherapy (Bullen et al., 1976) .
The combination of CEA and nonspecific tumour markers may help in the identification of high-risk patients. It appears that, using a discriminant function based on CEA and APRPs, patients with a negative discriminant index have a worse prognosis than those in which it is positive. This is mainly, but not wholly, due to the value of the CEA. The ability of the discriminant to separate the probable failures from the probable successes in patients where the CEA is < 100 ng/ml is the main advantage of the system. It is well established that CEA values > 100 ng/ml carry a poor prognosis.
Current experience of CEA tests, and their use in combination with non-specific indicators, suggests that 2-3-monthly blood tests are needed ifthe system is going to be given a real chance to provide early warning. Obviously, high risk patients should be given priority, especially if the clinician intends to use the information as a possible indication for additional therapy, whilst the tumour load is low and the patient is in a good general state of health. 
